Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

By sjmartinez • July 18, 2023

Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. PMID: 37460276.

Tags: covid-19, Nebuliser therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Clinical phenotypes in acute and chronic infarction explained through human ventricular electromechanical modelling and simulations

Zhou X, Wang ZJ, Camps J, Tomek J, Santiago A, Quintanas A, Vazquez M, Vaseghi M, Rodriguez B. Clinical phenotypes in acute and chronic infarction[...]

Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium

Nguyen T, Koric A, Chang CE, Barul C, Radoi L, Serraino D, Purdue MP, Kelsey KT, McClean MD, Negri E, Edefonti V, Moysich K, Zhang[...]

Expert Perspective: Management of Relapses in Giant Cell Arteritis

Alba MA, Unizony S, Warrington KJ, Murgia G, Prieto-González S, Salvarani C, Matteson EL, Kermani TA. Expert Perspective: Management of Relapses in Giant Cell Arteritis.[...]